A Phase I-II Clinical Trial of Pegylated Liposomal Doxorubicin (Doxil®) in Combination With BIBF 1120 in Patients With Ovarian Cancer: Hoosier Oncology Group GYN10-149

For full description, see www.clinicaltrials.gov.

Abstracts/Posters/Presentations:

• M.C. deLeon, A. Arnold, E.C. Rossi, J. Case, C. Johnson, Y. Zeng, D. Matei. Phase I trial of pegylated liposomal doxorubicin in combination with BIBF 1120 (nintedanib) in platinum-resistant ovarian cancer: Hoosier Oncology Group GYN10-149. Accepted to the gynecologic cancer general poster session at the ASCO Annual Meeting May 30 – June 3, 2014, Chicago IL. J Clin Oncol 32:5s, 2014 (suppl; abstr 5541^). See abstract.